Philadelphia, PA - November 15, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced results from a 48-week Open Label Extension (OLE) safety study in which Ferric ...
Oral ferric citrate increased hemoglobin levels in patients with chronic kidney disease. The treatment was effective in correcting anemia within 2 weeks of initiation. Diarrhea and constipation were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback